07:00 , Oct 5, 2015 |  BioCentury  |  Emerging Company Profile

Picking a PCSK9

As the first mAbs against PCSK9 are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc. has assembled a test kitchen of screens for small molecules with...
07:00 , Sep 21, 2015 |  BioCentury  |  Product Development

Alnylam's lipid sync

Alnylam Pharmaceuticals Inc. and The Medicines Co. think an RNA-based approach to lowering LDL-C could help patients adhere to treatment by enabling them to receive therapy at the same time they are normally scheduled for...
07:00 , May 8, 2014 |  BC Innovations  |  Strategy

Temple building

The Temple University School of Pharmacy has teamed up with MorphoSys AG to bring industry-quality antibody technology in-house. The partnership expands MorphoSys' access to early stage research and adds to the toolkit of discovery capabilities...
08:00 , Feb 6, 2014 |  BC Innovations  |  Targets & Mechanisms

PCSK9 peptide inhibitors

Although at least 10 companies are chasing inhibitors of PCSK9 for decreasing low-density lipoprotein cholesterol, the compounds dominating the field are antibodies or siRNAs that require injection. Roche 's Genentech Inc. unit and a separate...
07:00 , Apr 30, 2012 |  BioCentury  |  Product Development

PCSK9 bandwagon

While antibody inhibitors of proprotein convertase subtilisin/kexin 9 have begun to report proof-of-concept data as lipid-lowering agents, other approaches to PCSK9 inhibition are just now moving into the clinic. Small molecule programs could have an...
07:00 , Apr 30, 2012 |  BioCentury  |  Product Development

Beyond statins: LDL diversity

No fewer than 20 companies are working on next-generation lipid-lowering agents intended to improve upon the benefits of statins, which lower LDL-C and reduce the risk of cardiovascular events but still leave millions of people...